13 results about "Primary disease" patented technology

The invention discloses a health state monitoring management system for a traditional Chinese medicine AI digital health manager, and belongs to the technical field of health management. Comprising an information receiving module; a health index calculation module; a personal case library construction module; a primary disease screening module; a secondary disease screening module; and a disease diagnosis module. According to the invention, by constructing a personal case library, adopting primary and secondary grading screening mechanisms and combining with an analytic hierarchy process to dynamically set feature weights and standardize data, accurate personalized health state monitoring, efficient disease screening and diagnosis and scientific quantitative evaluation effects conforming to traditional Chinese medicine syndrome differentiation logic are achieved; the problems of insufficient utilization of personalized health data, low disease screening efficiency and unscientific health index quantitative evaluation in the prior art are solved.

The present disclosure relates, at least in part, to compositions comprising constant natural killer T (iNKT) cells (e.g., unmodified allogeneic iNKT cells), and uses of the compositions comprising the iNKT cells to treat a disease or a symptom or complication of a disease (e.g., a viral infection, a disease secondary to a primary disease (e.g., a neurological disease). The present invention relates to a method for treating acute respiratory distress syndrome (ARDS) and / or organ failure associated therewith (e.g., viral infection).

The invention discloses a health state monitoring management system for a traditional Chinese medicine AI digital health manager, and belongs to the technical field of health management. Comprising an information receiving module; a health index calculation module; a personal case library construction module; a primary disease screening module; a secondary disease screening module; and a disease diagnosis module. According to the invention, by constructing a personal case library, adopting primary and secondary grading screening mechanisms and combining with an analytic hierarchy process to dynamically set feature weights and standardize data, accurate personalized health state monitoring, efficient disease screening and diagnosis and scientific quantitative evaluation effects conforming to traditional Chinese medicine syndrome differentiation logic are achieved; the problems of insufficient utilization of personalized health data, low disease screening efficiency and unscientific health index quantitative evaluation in the prior art are solved.

Methods for predicting a cutaneous primary site of disease are described. The methods may comprise, for example, receiving, using one or more processors, sequence read data associated with a sample from the individual, selecting, using the one or more processors, a plurality of reads from the sequence read data, determining, using the one or more processors, an ultra-violet (UV) signature metric based on the selected plurality of reads, inputting, using the one or more processors, the UV signature metric into a statistical model, and predicting, using the one or more processors, the primary site of the disease in the individual based on an output of the statistical model.

The pharmaceutical compound or the pharmaceutically acceptable salt thereof is used for preventing or treating the following diseases by simultaneously inhibiting autotaxin (ATX) and activating peroxisome proliferator-activated receptor gamma (PPAR gamma): a) fibroproliferative diseases, in particular interstitial lung diseases (ILD) and / or liver diseases, and b) fibroproliferative diseases, in particular interstitial lung diseases (ILD) and / or liver diseases; the present invention relates to a pharmaceutical composition for treating hepatitis, such as various hepatitis and / or non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH) and / or cirrhosis, where said ILD may be a primary disease, preferably idiopathic pulmonary fibrosis and / or sarcoidosis and / or interstitial pneumonia, or said ILD is a complication associated with an autoimmune and / or inflammatory and / or metabolic disease, or a pharmaceutical composition comprising said ILD. Preferably rheumatoid arthritis ILD and / or scleroderma ILD and / or myositis ILD and / or diabetes ILD and / or cardiovascular disease ILD; and / or b) inflammatory and / or autoimmune diseases, preferably rheumatoid arthritis and / or scleroderma; and / or c) cancer, in particular lung and / or hepatocellular carcinoma and / or pancreatic cancer and / or glioblastoma and / or neuroblastoma; and / or d) a metabolic disease, in particular diabetes mellitus type 1 and / or diabetes mellitus type 2 and / or obesity, having a formula selected from the group consisting of formulae (A), (B), (C), (D), (E), (F), (G) and (H).

The present disclosure, at least in part, relates to compositions comprising invariant natural kill T (iNKT) cells (e.g., unmodified, allogeneic iNKT cells), and methods of using the compositions comprising the iNKT cells for treating a disease, or a symptom or complication of a disease (e.g., viral infection, acute respiratory distress syndrome (ARDS) secondary to a primary disease (e.g., viral infection) and / or its associated organ failure).

This invention belongs to the food or pharmaceutical field, specifically relating to a probiotic and prebiotic composition, its preparation process, and its application. The composition includes probiotics, resistant dextrin, xylooligosaccharides, fructooligosaccharides, stachyose, erythritol, and cranberry powder, prepared using a fluidized bed spray granulation process. As an adjuvant to antibiotics, this composition has been verified in animal and clinical trials to synergistically treat upper / lower respiratory tract infections and urinary tract infections, shorten symptom duration, accelerate recovery from the primary disease, maintain intestinal flora diversity, increase the abundance of beneficial bacteria such as Bifidobacteria, reduce the incidence of adverse reactions, and alleviate antibiotic-associated diarrhea. This invention provides a microecological restoration solution for antibiotic treatment, possessing clear clinical value and technological feasibility.

The present invention provides compounds of formula (I) or an enantiomer thereof, particularly the R-enantiomer, a diastereomer thereof, its hydrates, its solvates, its crystal forms, its tautomers or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, X and A are as defined herein. Said compounds of formula (I) are inhibitors of insulin-like growth factor 2 mRNA binding proteins (IGF2BP). Provided are novel inhibitors of IGF2BPs and processes for manufacturing the same. The invention further relates to a compound of formula (I) or a pharmaceutical composition for use in the treatment of any malignant disorder, including primary disease, metastases or recurrent neoplasia, which exhibits expression of IGF2BP1 in a manner amenable to the therapeutic intervention.

The invention relates to the technical field of chronic disease prevention and treatment, and discloses a grassroots chronic disease screening and prevention center intelligent management platform which comprises a multi-disease follow-up visit management module, a signing-fulfillment-integral closed loop module, a risk assessment and health intervention module, a cross-system data linkage module, a data statistics and evaluation module and a multi-terminal adaptation and safety module. Through the multi-disease integrated follow-up management technology, the general situation that one person has multiple diseases can be adapted, combined filing of multiple chronic diseases and personalized follow-up plan generation are supported, follow-up tasks can be intelligently combined, the follow-up state can be accurately tracked, the medical care operation efficiency is remarkably improved, and a more efficient solution is provided for follow-up management of the basic chronic diseases.

Methods and systems disclosed herein relate to detecting a presence or an absence of a second primary disease in a subject. The methods may comprise performing a workflow comprising a minimal residual disease (MRD) assay on a biological sample and using a result of the workflow to detect a presence or absence of a second primary disease in the subject.

The invention relates to a system (1) for providing a warning in respect of the state of health of a patient (P1...PN) during intensive treatment of a malign primary disease, the system comprising • a device (W1), which can be worn on the body of the patient (P1) and serves to measure a plurality of vital parameters and • an evaluation device (A), • wherein vital parameters are selected from a group including pulse, pulse variation, respiratory rate, temperature, electrical skin resistance, oxygen saturation, blood pressure, acceleration, changes in orientation, and activity, • the wearable device (W1) is designed such that the plurality of vital parameters are continuously recorded, • the wearable device (W1) furthermore has at least an interface (I / O) in order to be able to pass data on to the evaluation device (A), • the evaluation device (A) furthermore has at least an interface (I / O) for receiving data recorded by the wearable device (W1), • the evaluation device (A) has a processing unit (CPU), • the evaluation device (A) has a data input device (HID) and a data output device (DIS), • first received data recorded by the data output device (DIS) can be displayed in order for a user (D1...DN) to distinguish and classify regular data and irregular data, • the data input device (HID) is designed to accept the result of distinction and classification of regular data and irregular data made by the user (D1...DN), • the evaluation device (A) has a neural network (KI), and the neural network has previously been trained onto regular data in a self-supervised manner, • the evaluation device (A) evaluates second received data by means of the neural network (KI), the second received data a temporally subsequent to the first data, and the neural network classifies regular data and irregular data, and • the evaluation device (A) is also designed to inform the user by way of a warning if irregular data are found that indicate an imminent infectiological or immunological complication.

The application relates to a computing device for identifying pharmacological phenotypes. Pharmacological phenotypes are predicted for patients who exhibit or are likely to exhibit a primary disease or complication. A machine learning engine may generate statistical models based on training data from a trained patient to predict pharmacological phenotypes, including drug responses and doses, drug adverse events, risk of diseases and complications, drug-gene interactions, drug-drug interactions, and multi-pharmacy interactions. The model can then predict the pharmacological phenotype of a new patient and can make decisions in clinical and research contexts, including drug selection and dosage, changes in drug treatment regimens, multi-pharmacy optimization, monitoring, and the like, to benefit from additional predictive capabilities, as well as to improve the ability to predict the pharmacological phenotype of the new patient. Therefore, adverse events and drug abuse are avoided, drug response is improved, patient recovery results are improved, treatment cost is reduced, public health benefits are improved, and research efficiency in pharmacology and other biomedical fields is improved.

The invention discloses a health data management method and system based on big data analysis, and belongs to the technical field of health management. Performing primary disease risk estimation through a preset first disease reasoning model to obtain a first estimated primary disease, and removing primary disease information of the patient from the first estimated primary disease to obtain a second estimated primary disease of the patient; whether the disease screening is carried out in the corresponding address area is judged according to the number of patients taking the disease as the primary disease and the number of patients taking the disease as the second estimated primary disease, so that the accurate screening of the disease target and the area target is realized, the singleness of the screening target disease is avoided, the effective range of the screening target disease is expanded, and the screening efficiency is improved. Meanwhile, the screening efficiency and the effective pertinence are improved.